Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Assets (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Assets for 12 consecutive years, with $158.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets rose 13.87% year-over-year to $158.3 million, compared with a TTM value of $158.3 million through Sep 2025, up 13.87%, and an annual FY2024 reading of $120.5 million, down 40.27% over the prior year.
  • Assets was $158.3 million for Q3 2025 at CytomX Therapeutics, down from $175.1 million in the prior quarter.
  • Across five years, Assets topped out at $434.2 million in Q1 2021 and bottomed at $98.5 million in Q1 2025.
  • Average Assets over 5 years is $236.5 million, with a median of $221.2 million recorded in 2023.
  • Peak annual rise in Assets hit 13.87% in 2025, while the deepest fall reached 46.67% in 2025.
  • Year by year, Assets stood at $339.4 million in 2021, then dropped by 23.13% to $260.9 million in 2022, then fell by 22.65% to $201.8 million in 2023, then plummeted by 40.27% to $120.5 million in 2024, then soared by 31.3% to $158.3 million in 2025.
  • Business Quant data shows Assets for CTMX at $158.3 million in Q3 2025, $175.1 million in Q2 2025, and $98.5 million in Q1 2025.